Unicycive Therapeutics, Inc. (NASDAQ: UNCY) reported Q2 EPS of ($0.29), $0.09 worse than the analyst estimate of ($0.20).

For earnings history and earnings-related data on Unicycive Therapeutics, Inc. (UNCY) click here.